Duvic, M., Olsen, E. A., Breneman, D., Pacheco, T. R., Parker, S., Vonderheid, E. C., … Geskin, L. J. (2008). Vorinostat provides prolonged safety and clinical benefit to patients with advanced CTCL. In ANNALS OF ONCOLOGY (Vol. 19, pp. 161–161). Lugano, SWITZERLAND: OXFORD UNIV PRESS.

Duvic, M., E. A. Olsen, D. Breneman, T. R. Pacheco, S. Parker, E. C. Vonderheid, J. L. Ricker, et al. “Vorinostat provides prolonged safety and clinical benefit to patients with advanced CTCL.” In ANNALS OF ONCOLOGY, 19:161–161. OXFORD UNIV PRESS, 2008.

Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, et al. Vorinostat provides prolonged safety and clinical benefit to patients with advanced CTCL. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2008. p. 161–161.

Duvic, M., et al. “Vorinostat provides prolonged safety and clinical benefit to patients with advanced CTCL.” ANNALS OF ONCOLOGY, vol. 19, OXFORD UNIV PRESS, 2008, pp. 161–161.

Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Vorinostat provides prolonged safety and clinical benefit to patients with advanced CTCL. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2008. p. 161–161.